

# Salvatore Piano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6872376/publications.pdf>

Version: 2024-02-01

103  
papers

6,694  
citations

94433

37  
h-index

64796

79  
g-index

107  
all docs

107  
docs citations

107  
times ranked

4926  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	3.7	571
2	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	12.1	405
3	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
4	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
5	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i> , 2015, 62, 567-574.	7.3	283
6	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
7	Acute alcohol intoxication. <i>European Journal of Internal Medicine</i> , 2008, 19, 561-567.	2.2	270
8	Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2013, 59, 482-489.	3.7	232
9	Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. <i>Hepatology</i> , 2016, 63, 983-992.	7.3	225
10	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
11	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
12	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. <i>Hepatology</i> , 2016, 63, 1299-1309.	7.3	186
13	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
14	How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists. <i>Journal of Hepatology</i> , 2013, 59, 257-264.	3.7	146
15	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
16	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	4.4	127
17	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 438-445.e5.	4.4	125
18	Infections complicating cirrhosis. <i>Liver International</i> , 2018, 38, 126-133.	3.9	122

#	ARTICLE	IF	CITATIONS
19	Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. <i>Hepatology</i> , 2019, 70, 319-333.	7.3	114
20	Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. <i>Hepatology</i> , 2013, 57, 266-276.	7.3	104
21	Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2016, 64, 813-822.	3.7	104
22	Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. <i>Liver International</i> , 2020, 40, 2394-2406.	3.9	103
23	Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 1177-1184.	3.7	101
24	Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. <i>Liver International</i> , 2019, 39, 98-105.	3.9	100
25	Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. <i>Gut</i> , 2018, 67, 1892-1899.	12.1	98
26	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	3.7	96
27	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. <i>Gut</i> , 2015, 64, 1616-1622.	12.1	86
28	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
29	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
30	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
31	Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. <i>Journal of Hepatology</i> , 2021, 75, S101-S117.	3.7	66
32	Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. <i>Liver International</i> , 2015, 35, 1508-1515.	3.9	63
33	Management of ascites and hepatorenal syndrome. <i>Hepatology International</i> , 2018, 12, 122-134.	4.2	62
34	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.9	57
35	Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. <i>Hepatology</i> , 2021, 73, 1909-1919.	7.3	53
36	Assessment of alcohol consumption in liver transplant candidates and recipients: The best combination of the tools available. <i>Liver Transplantation</i> , 2014, 20, 815-822.	2.4	46

#	ARTICLE	IF	CITATIONS
37	Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?. <i>Journal of Hepatology</i> , 2011, 55, 491-496.	3.7	40
38	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1188-1196.e3.	4.4	39
39	Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 681-684.	1.6	38
40	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
41	Affective and Psychiatric Disorders in Celiac Disease. <i>Digestive Diseases</i> , 2008, 26, 140-148.	1.9	37
42	Renal Function in Cirrhosis: A Critical Review of Available Tools. <i>Seminars in Liver Disease</i> , 2018, 38, 230-241.	3.6	37
43	Sepsis-induced acute kidney injury in patients with cirrhosis. <i>Hepatology International</i> , 2016, 10, 115-123.	4.2	36
44	Why and how to measure renal function in patients with liver disease. <i>Liver International</i> , 2017, 37, 116-122.	3.9	35
45	New <scp>ICA</scp> criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine?. <i>Liver International</i> , 2015, 35, 2108-2114.	3.9	33
46	Natural history of acute kidney disease in patients with cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 578-583.	3.7	32
47	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. <i>American Journal of Medicine</i> , 2017, 130, 372-375.	1.5	31
48	Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. <i>Scientific Reports</i> , 2017, 7, 1829.	3.3	30
49	Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List. <i>Transplantation</i> , 2020, 104, e188-e198.	1.0	30
50	COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. <i>Gut</i> , 2021, 70, 1914-1924.	12.1	30
51	Changes in the epidemiology and management of bacterial infections in cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 437-445.	8.9	29
52	Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections. <i>American Journal of Gastroenterology</i> , 2017, 112, 1575-1583.	0.4	28
53	The Treatment of Hepatorenal Syndrome. <i>Digestive Diseases</i> , 2015, 33, 548-554.	1.9	25
54	Spontaneous bacterial peritonitis due to carbapenemase-producing <i>Klebsiella pneumoniae</i> . <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1234-1237.	1.6	22

#	ARTICLE	IF	CITATIONS
55	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 107-114.	3.7	21
56	An Integrated Review of the Hepatorenal Syndrome. <i>Annals of Hepatology</i> , 2021, 22, 100236.	1.5	20
57	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022, 4, 100513.	4.9	19
58	Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 626-632.	1.6	18
59	Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 358-366.e8.	4.4	16
60	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
61	Location and allocation: Inequity of access to liver transplantation for patients with severe acute-on-chronic liver failure in Europe. <i>Liver Transplantation</i> , 2022, 28, 1429-1440.	2.4	16
62	Hepatorenal Syndrome. <i>Contributions To Nephrology</i> , 2011, 174, 46-55.	1.1	15
63	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1278-1285.e2.	1.5	15
64	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.9	13
65	Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 270-277.	1.3	12
66	Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation?. <i>Clinics in Liver Disease</i> , 2021, 25, 357-372.	2.1	10
67	Corrigendum to "Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites" [J Hepatol 2015;62:968-974]. <i>Journal of Hepatology</i> , 2015, 63, 290.	3.7	9
68	Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 284-290.	1.6	9
69	Acute-on-Chronic Liver Failure in Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4406.	2.4	9
70	Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 94-96.	8.9	7
71	The liver: another organ involved in Muir Torre syndrome?. <i>Familial Cancer</i> , 2012, 11, 7-12.	1.9	6
72	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. <i>Journal of Hepatology</i> , 2019, 70, e53.	3.7	5

#	ARTICLE	IF	CITATIONS
73	Current Concepts on Bacterial and Fungal Infections in Cirrhosis. <i>Clinical Liver Disease</i> , 2019, 14, 87-91.	2.1	5
74	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
75	Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors?. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 273-275.	0.9	4
76	Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI" To be or not to be. <i>Journal of Hepatology</i> , 2015, 62, 744-746.	3.7	4
77	Reply. <i>Hepatology</i> , 2016, 64, 998-999.	7.3	4
78	Identifying the four shades of acute decompensation of cirrhosis. <i>United European Gastroenterology Journal</i> , 2021, 9, 421-422.	3.8	4
79	Low myocardial mechano-energetic efficiency is an independent predictor of prognosis in advanced chronic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e656-e661.	1.6	4
80	Immune thrombocytopenic purpura and Kaposi's sarcoma in a liver transplant recipient. <i>Transplant International</i> , 2012, 25, e50-e52.	1.6	3
81	Tocilizumab for severe COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e659-e660.	3.9	3
82	Metabolomics to Predict Acute Kidney Injury in Cirrhosis. <i>Hepatology</i> , 2021, 74, 2339-2341.	7.3	3
83	Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin?. <i>Liver Transplantation</i> , 2015, 21, 1335-1337.	2.4	2
84	Reply to: "To close the stable door before the horse has bolted" <i>Journal of Hepatology</i> , 2014, 60, 680-681.	3.7	1
85	Reply. <i>Hepatology</i> , 2016, 64, 318-318.	7.3	1
86	Brexit from current guideline recommendations?. <i>Gut</i> , 2016, 65, 1919.1-1919.	12.1	1
87	SAT-115-Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e681.	3.7	1
88	Predicting Outcomes of Liver Transplantation in Patients With Nonalcoholic Steatohepatitis: Pretransplant Renal Function Is Key. <i>Liver Transplantation</i> , 2019, 25, 362-364.	2.4	1
89	Effects of a reorganization of cirrhosis care during the lockdown for SARS-CoV-2 outbreak. <i>JHEP Reports</i> , 2021, 3, 100229.	4.9	1
90	Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure" <i>Journal of Hepatology</i> , 2021, 75, 1010-1012.	3.7	1

#	ARTICLE	IF	CITATIONS
91	Acute on chronic liver failure in cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 273-275.	8.9	1
92	Reply to: "Coordinated care models in cirrhosis; the need for further randomized controlled trials". <i>Journal of Hepatology</i> , 2014, 60, 466-467.	3.7	0
93	Reply. <i>Hepatology</i> , 2016, 64, 2268-2269.	7.3	0
94	Reply. <i>Hepatology</i> , 2016, 64, 2260-2262.	7.3	0
95	Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome. , 2019, , 487-492.e2.		0
96	FRI-403-Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome. <i>Journal of Hepatology</i> , 2019, 70, e572.	3.7	0
97	LBP-15-Urinary Liver Fatty-Acid-Binding Protein (uL-FABP) improves accuracy of MELD score to predict short-term mortality in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e147-e149.	3.7	0
98	THU-044-Cystatin C as a predictive biomarker of ACLF development and mortality on the liver transplant waiting list. <i>Journal of Hepatology</i> , 2019, 70, e179.	3.7	0
99	Acute Kidney Injury and Hepatorenal Syndrome. , 2019, , 147-161.		0
100	Pathophysiology and Management of the Hepatorenal Syndrome. , 2019, , 774-781.e2.		0
101	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. <i>Journal of Hepatology</i> , 2020, 73, S738.	3.7	0
102	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1510-1511.	4.4	0
103	REPLY:. <i>Hepatology</i> , 2021, 74, 2324-2325.	7.3	0